000 | 01919 a2200529 4500 | ||
---|---|---|---|
005 | 20250515053654.0 | ||
264 | 0 | _c20080214 | |
008 | 200802s 0 0 chi d | ||
022 | _a0253-3766 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aXu, Jian-ming | |
245 | 0 | 0 |
_a[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan]. _h[electronic resource] |
260 |
_bZhonghua zhong liu za zhi [Chinese journal of oncology] _cAug 2006 |
||
300 |
_a578-82 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xpharmacology |
650 | 0 | 4 |
_aApoptosis _xdrug effects |
650 | 0 | 4 |
_aCamptothecin _xanalogs & derivatives |
650 | 0 | 4 |
_aCell Cycle _xdrug effects |
650 | 0 | 4 | _aCell Line, Tumor |
650 | 0 | 4 |
_aCell Survival _xdrug effects |
650 | 0 | 4 |
_aColonic Neoplasms _xenzymology |
650 | 0 | 4 |
_aDNA Topoisomerases, Type I _xmetabolism |
650 | 0 | 4 | _aDrug Synergism |
650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
650 | 0 | 4 | _aGefitinib |
650 | 0 | 4 | _aHT29 Cells |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInhibitory Concentration 50 |
650 | 0 | 4 | _aIrinotecan |
650 | 0 | 4 |
_aMitogen-Activated Protein Kinase Kinases _xmetabolism |
650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xmetabolism |
650 | 0 | 4 |
_aQuinazolines _xpharmacology |
650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
700 | 1 | _aLi, Yue-min | |
700 | 1 | _aWang, Yan | |
700 | 1 | _aZhao, Chuan-hua | |
700 | 1 | _aYuan, Shou-jun | |
700 | 1 | _aYang, Wu-wei | |
700 | 1 | _aLi, Zhi-qiang | |
700 | 1 | _aHan, Yu | |
700 | 1 | _aAzzariti, Amalia | |
700 | 1 | _aParadiso, Angelo | |
773 | 0 |
_tZhonghua zhong liu za zhi [Chinese journal of oncology] _gvol. 28 _gno. 8 _gp. 578-82 |
|
999 |
_c16800109 _d16800109 |